Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Entera Bio Ltd.NASDAQ: ENTX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 67.1% from a year ago
Cash & equivalents stood at $4.14M at the end of Q1 FY2026, down 67.1% from a year earlier and down 41.8% from the prior quarter. Over 3 fiscal years it compounded at -16.7% a year.
Context
- Cash & equivalents amounted to 31.5% of total assets at the end of Q1 FY2026, down 26.7 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -67.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 7.11M USD
- Year-over-year change
- -17.9%
- 4-year CAGR
- -26.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.11M | -17.9% |
| FY2024 | 2024-12-31 | 8.66M | -21.4% |
| FY2023 | 2023-12-31 | 11.02M | -10.5% |
| FY2022 | 2022-12-31 | 12.31M | -50.6% |
| FY2021 | 2021-12-31 | 24.89M | — |
Cash & Equivalents vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 cash & equivalents of $4.14M is the 9th highest of the 10 companies compared; the peer median is $35M.
- Its year-over-year change of -67.1% is the lowest of 10, against a peer median of +1.3%.
- Cash & equivalents amounts to 31.5% of total assets for ENTX, versus a peer median of 25.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | Mar 2026 | $59.96M | +43.5% | +1.9% | 89.8% |
| Mar 2026 | $56.13M | +14.8% | -28.3% | 95.1% | |
| Mar 2026 | $51.8M | +71.7% | -25.4% | 38.8% | |
| Mar 2026 | $47.32M | -9.8% | -3.9% | 17.4% | |
| Mar 2026 | $35M | +89.3% | -74.4% | 18.8% | |
| Mar 2026 | $29.83M | -49.3% | -34.5% | 25.4% | |
| Mar 2026 | $26.27M | -34.2% | -1.5% | 52.8% | |
| Mar 2026 | $6.3M | +1.3% | -36.7% | 21.2% | |
| Mar 2026 | $4.14M | -67.1% | -16.7% | 31.5% | |
| Apr 2026 | $1.48M | -22.7% | -53.5% | 9.9% | |
| Peer median (excluding ENTX) | $35M | +1.3% | -28.3% | 25.4% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.